← Insider buys

SOPH

SOPHiA GENETICS SA · Healthcare

Insiders bought $99K of SOPHiA GENETICS SA in the last 12 months

1 insider bought on 1 day.

$99KBought, 12 mo
$4.0MSold, 12 mo
$630.8MMarket cap

SOPH over the last year

Insider buy filed (1 day)

Largest buyers, last 12 months

SOPH after insider buys

3 months after each buy, from the first price a copier could get.

1 buy has 3 months of prices so far. A record shows here at 3.

Every filing

47 insider filings since 2026, newest first

SOPHSell

Philippe Menu · Chief Medical Officer

$36K−2.5%Oct 14
SOPHSell

Zhenyu Xu · Chief Scientific Officer

$29K−0.7%Oct 14
SOPHSell

Jurgi Camblong · Executive Chair

$62K−0.3%Oct 14
SOPHSell

Well Daan Van · Chief Legal Officer

$50K−1.8%Oct 7
SOPHSell

Manuela Valente · Chief People Officer

$34K−2.0%Oct 7
SOPHSell

Abhimanyu Verma · Chief Technology Officer

$43K−3.1%Oct 7
SOPHSell

Philippe Menu · Chief Medical Officer

$60K−3.5%Oct 7
SOPHSell

Jurgi Camblong · Executive Chair

$327K−1.2%Oct 7
SOPHSell

Zhenyu Xu · Chief Scientific Officer

$60K−1.3%Oct 7
SOPHSell

Ross Muken · Chief Executive Officer

$80K−1.5%Oct 7
SOPHSell

Philippe Menu · Chief Medical Officer

$39K−2.3%Sep 16
SOPHSell

Zhenyu Xu · Chief Scientific Officer

$32K−0.7%Sep 16
SOPHSell

Well Daan Van · Chief Legal Officer

$47K−1.8%Sep 14
SOPHSell

Jurgi Camblong · Executive Chair

$65K−0.2%Sep 14
SOPHSell

Kathy L Hibbs · Director

$51K−6.1%Sep 10
SOPHSell

Zhenyu Xu · Chief Scientific Officer

$89K−1.8%Aug 31
SOPHSell

Philippe Menu · Chief Medical Officer

$43K−2.3%Aug 26
SOPHSell

Kathy L Hibbs · Director

$54K−5.7%Aug 26
SOPHSell

Abhimanyu Verma · Chief Technology Officer

$85K−5.5%Aug 26
SOPHSell

Manuela Valente · Chief People Officer

$79K−4.5%Aug 21
SOPHSell

Zhenyu Xu · Chief Scientific Officer

$163K−3.4%Aug 21
SOPHSell

Philippe Menu · Chief Medical Officer

$38K−2.2%Aug 14
SOPHSell

Zhenyu Xu · Chief Scientific Officer

$30K−0.7%Aug 14
SOPHSell

Abhimanyu Verma · Chief Technology Officer

$38K−2.7%Aug 10
SOPHSell

Jurgi Camblong · Executive Chair

$209K−0.8%Aug 10
SOPHSell

Zhenyu Xu · Chief Scientific Officer

$145K−3.3%Aug 7
SOPHSell

Abhimanyu Verma · Chief Technology Officer

$35K−2.6%Aug 5
SOPHSell

Jurgi Camblong · Executive Chair

$138K−0.6%Aug 5
SOPHSell

Zhenyu Xu · Chief Scientific Officer

$69K−1.6%Aug 5
SOPHSell

Philippe Menu · Chief Medical Officer

$28K−2.2%Jul 28
SOPHSell

Jurgi Camblong · Executive Chair

$286K−1.3%Jul 22
SOPHSell

Philippe Menu · Chief Medical Officer

$29K−2.1%Jul 14
SOPHSell

Jurgi Camblong · Executive Chair

$48K−0.2%Jul 14
SOPHSell

Jurgi Camblong · Executive Chair

$93K−0.5%Jul 8
SOPHSell

Abhimanyu Verma · Chief Technology Officer

$27K−2.7%Jul 7
SOPHSell

Zhenyu Xu · Chief Scientific Officer

$38K−1.2%Jul 7
SOPHSell

Ross Muken · Chief Executive Officer

$51K−1.4%Jul 7
SOPHSell

Philippe Menu · Chief Medical Officer

$38K−3.1%Jul 7
SOPHSell

Jurgi Camblong · Executive Chair

$118K−0.6%Jul 7
SOPHSell

Jurgi Camblong · Executive Chair

$507K−2.3%Jul 1
SOPHSell

Jurgi Camblong · Chief Executive Officer

$298K−1.4%Jun 29
SOPHSell

Abhimanyu Verma · Chief Technology Officer

$38K−3.4%Jun 26
SOPHSell

Philippe Menu · Chief Medical Officer

$28K−2.0%Jun 26
SOPHSell

Jurgi Camblong · Chief Executive Officer

$45K−0.2%Jun 11
SOPHBuy

George Cardoza · Chief Financial Officer

$99K+6.9%Jun 5
SOPHSell

Kathy L Hibbs · Director

$35K−8.0%May 13
SOPHSell

Jurgi Camblong · Chief Executive Officer

$43K−0.2%May 12
About SOPHiA GENETICS SA

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. The company has a partnership with Synnovis to bring blood-based cancer testing to patients in the United Kingdom. The company was incorporated in 2011 and is based in Rolle, Switzerland.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.